Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy

Abstract

Abstract: Objective To observe the therapeutic effects of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy. Methods Eighty-five patient with liver cirrhosis complicated by hepatic encephalopathy were divided into therapy group (n=45) and control group (n=40). Patients in the control group were treated with routine comprehensive therapy, and those in the therapy group received additional intravenous administration with 40 ml L-ornithine-L-aspartate in 250 ml 10% glucose and saline (once daily, 7 days for a treatment course). Results L-ornithine-L-aspartase significantly decreased blood ammonia and improved hepatic function (P<0.05 or 0.01). The therapeutic effects of therapy group was better than that of the control group (P<0.05), and no significant side effect was observed in L-ornithine-L-aspartate treatment. Conclusion L-ornithine-L-aspartate is effective for hepatic encephalopathy and has not obvious side effect.

CLC Number:

R575.2

CHEN Ming-fei, LI Ru-cheng, CHEN Chang-hong, GAO Xiao-ci. Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy[J]. Journal of Southern Medical University, 2005, 25(06): 718-719,722.

References

[1] Lun LG. Pathogenesis of hepatic encephalopathy[J]. Chin J Hepatol,2004, 12(5):304-6.
[2] 姜忠妹,裴的善.肝性脑病药物的去氨作用[J].中国药学(Chin Pharm),2004,13(7):78-9.
[3] 中华医学会传染病与寄生虫病学分会、肝病学分会.病毒性肝炎防治方案[J].中华传染病杂志(Chin JInfectDis),2001,19(1):56-62.
[4] MarkB,TaylorM.潘国宗译.胃肠急症学[M].北京:中国协和医科大学出版社,1998.321-38.
[5] 姜树椿.传染病基础与临床[M].北京:军事科学出版社,1999.384-6.
[6] 蒋树林,姚希贤.幽门螺杆菌粘膜致病机理研究现状[J].胃肠病学和肝病学杂志(J Gastroenterol Heper),1997,6(2):100-3.
[7] 王卫卫,杨希山,吴平生,等.纤维化及正常肝组织中血管紧张素Ⅱ1型受体mRNA的表达[J].第一军医大学学报,2003,23(5):477-9Wang WW, Yang XS, Wu PS, et al. Expressions of angiotensin Ⅱtype 1 receptor mRNA in fibrotic and normal liver tissues[J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2003, 23(5):477-9.
[8] 朱宁川,陈岩.肝病肠道菌群失调与肠源性内毒素血症[J].中国微生态学杂志(Chin J Microeco1),2004,16(1):61-2
[9] 刘厚鈺,石虹.门体性肝性脑病的治疗进展[J].中华消化杂志(Chin J Dig),1999,19(3):191-3.
[10] Ferenci P, Herneth A, Steindl P. Newer approaches to therapy of hepatic encephalopathy [J]. Seminliver Dis, 1996, 16(2):329-36.
[11] Kircheis G, Niling R, Held C, et al. The therapeutic efficacy of Lornithine-L-as partate infusions in patients with cirrhosis and hepatic encephalopathy:Results of splacebo-controlled,double-blind study[J]. Hepatology, 1997, 25(12):1351-60.
[12] Rees CJ, Oprpong K, AlMardini H, et al. Effect of L-ornithine-Laspartate on patients with and without TIPS undergoing glutamine challenge:a double blind, placebo controlled trial[J]. Gut, 2000, 47(4):571-4.